1. Home
  2. API vs TTRX Comparison

API vs TTRX Comparison

Compare API & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agora Inc.

API

Agora Inc.

HOLD

Current Price

$4.44

Market Cap

367.8M

Sector

Technology

ML Signal

HOLD

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

BUY

Current Price

$10.27

Market Cap

298.8M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
API
TTRX
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
367.8M
298.8M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
API
TTRX
Price
$4.44
$10.27
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$5.90
★ $25.00
AVG Volume (30 Days)
★ 128.6K
90.8K
Earning Date
11-18-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.12
N/A
Revenue Next Year
$16.06
$900.00
P/E Ratio
$92.30
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.14
$2.57
52 Week High
$5.50
$16.45

Technical Indicators

Market Signals
Indicator
API
TTRX
Relative Strength Index (RSI) 58.63 39.39
Support Level $4.32 $9.02
Resistance Level $4.60 $10.72
Average True Range (ATR) 0.16 0.85
MACD 0.03 -0.23
Stochastic Oscillator 87.98 9.94

Price Performance

Historical Comparison
API
TTRX

About API Agora Inc.

Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: